Skye Bioscience is a micro-cap pharmaceutical company aiming to become a major player in the weight loss drug market with its CB1 inhibitor, nimacimab. This drug is in Phase 2 trials and offers potential advantages over GLP-1 agonists, including fewer gastrointestinal side effects. However, nimacimab’s effectiveness in weight loss compared to existing treatments remains to be seen, making it a risky investment.